• DOI:10.1200/JCO.2016.72.0466
• Corpus ID: 44968689

Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.

@article{Chin2017BrachytherapyFP,
  title={Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.},
  author={Joseph L. Chin and R Bryan Rumble and Marisa Kollmeier and Elisabeth I. Heath and Jason A. Efstathiou and Tanya B. Dorff and Barry S. Berman and Andrew Feifer and Arthur D Jacques and D. Andrew Loblaw},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2017},
  volume={35 15},
  pages={
          1737-1743
        }
}

• J. Chin, R. B. Rumble, +7 authors D. Loblaw
• Published 27 March 2017
• Medicine, Physics
• Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Purpose To jointly update the Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer to account for new evidence. Methods An Update Panel conducted a targeted systematic literature review and identified more recent randomized controlled trials comparing dose-escalated external beam radiation therapy (EBRT) with brachytherapy in men with prostate cancer. Results Five randomized controlled trials provided the evidence for this update. Recommendations For patients with low-risk prostate cancer who require or choose active treatment, low-dose rate brachytherapy (LDR) alone, EBRT alone, and/or radical prostatectomy (RP) should be offered to eligible patients. For patients with intermediate-risk prostate cancer choosing EBRT with or without androgen-deprivation therapy, brachytherapy boost (LDR or high-dose rate [HDR]) should be offered to eligible patients. For low-intermediate risk prostate cancer (Gleason 7, prostate-specific antigen < 10 ng/mL or Gleason 6, prostate-specific antigen, 10 to 20 ng/mL), LDR brachytherapy alone may be offered as monotherapy. For patients with high-risk prostate cancer receiving EBRT and androgen-deprivation therapy, brachytherapy boost (LDR or HDR) should be offered to eligible patients. Iodine-125 and palladium-103 are each reasonable isotope options for patients receiving LDR brachytherapy; no recommendation can be made for or against using cesium-131 or HDR monotherapy. Patients should be encouraged to participate in clinical trials to test novel or targeted approaches to this disease. Additional information is available at www.asco.org/Brachytherapy-guideline and www.asco.org/guidelineswiki .